

DOCKET NO.: ISHT-1004

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Kenneth W. Dobie, et al.

Application No.: 10/714,796

Filing Date: November 17, 2003

For: ANTISENSE MODULATION OF KINESIN-LIKE EXPRESSION

Confirmation No.: Not Yet Assigned

Group Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

DATE OF DEPOSIT: *January 16, 2004*

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID, ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE UNITED STATES PATENT AND TRADEMARK OFFICE, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

Elizabeth A. McLoud

TYPED NAME: Elizabeth A. McLoud

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).



In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date

of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

- ☐ In accordance with § 1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

☐ Certification in Accordance with § 1.97(e) is attached; or

☐ The fee of **\$180.00** as set forth in § 1.17(p) is attached.

- ☐ In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

☐ Certification in Accordance with § 1.97(e) is attached;

or

☐ The fee of **\$180.00** as set forth in § 1.17(p) is attached.

- ☐ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of **\$180.00** as set forth in § 1.17(p).

- ☐ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

- ☒ Copies of references listed on the attached Form PTO-1449 are enclosed herewith
- ☒ Copies of references listed on the attached Form PTO 1449 are not required to be submitted pursuant to the June 30, 2003 recent revisions to 37 CFR § 1.98(a)(2)(i).


EXCEPT THAT:

- ☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
- ☒ In accordance with § 1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application:
- ☒ Copies of references **1-9 and 11** listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior Application No. **10/156,603**, filed **May 23, 2002**.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

- ☐ The relevance of those listed references which are not in the English language is as follows:
- ☒ There are no listed references which are not in the English language.

Date: *January 14, 2004*


Phillip A. Singer
Registration No. 40,176

WOODCOCK WASHBURN LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. ISHT-1004	Application No. 10/714,796
		Applicant Kenneth W. Dobie, et al.	
		Filing Date November 17, 2003	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	1	Blangy, et al., "Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo," <i>Cell</i> , 1995, 83, 1159-1169	
	2	Ferhat, et al., "Expression of the mitotic motor protein Eg5 in postmitotic neurons: implications for neuronal development," <i>J. Neurosci.</i> , 1998, 18, 7822-7835	
	3	Hansen, et al., "Activation of hex and mEg5 by retroviral insertion may contribute to mouse B-cell leukemia," <i>Oncogene</i> , 1999, 18, 6531-6539	
	4	Kaiser, et al., "All-trans-retinoic acid-mediated growth inhibition involves inhibition of human kinesin-related protein HsEg5," <i>J. Biol. Chem.</i> , 1999, 274, 18925-18931	
	5	Kapoor, et al., "Probing spindle assembly mechanisms with monastrol, a small molecule inhibitor of the mitotic kinesin, Eg5," <i>J. Cell Biol.</i> , 2000, 150, 975-988	
	6	Mayer, et al., "Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen," <i>Science</i> , 1999, 286, 971-974	
	7	Miki, et al., "All kinesin superfamily protein, KIF, genes in mouse and human," <i>Proc. Natl. Acad. Sci. USA</i> , 2001, 98, 7004-7011	
	8	Whitehead, et al., "Expanding the role of HsEg5 within the mitotic and post-mitotic phases of the cell cycle," <i>J. Cell Sci.</i> , 1998, 111, 2551-2561	
	9	Whitehead, et al., "The spindle kinesin-like protein HsEg5 is an autoantigen in systemic lupus erythematosus," <i>Arthritis Rheum.</i> , 1996, 39, 1635-1642	
	10	Weil, D., et al., "Targeting the kinesin Eg5 to monitor siRNA transfection in mammalian cells," Short Technical Reports, <i>BioTechniques</i> , 2002, 33(6), 1244-1248	
EXAMINER		DATE CONSIDERED	



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. ISHT-1004	Application No. 10/714,796
	Applicant Kenneth W. Dobie, et al.	
	Filing Date November 17, 2003	Group Not Yet Assigned
	Confirmation No. Not Yet Assigned	

U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass
	11	6,472,521 B1	10/29/02	Uhlmann, et al.	536	24.5
	12	2002/0165240	11/07/02	Kimball, et al.	514	258.1

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
	13	WO 03/030832 A3	04/17/03	PCT		

EXAMINER	DATE CONSIDERED
-----------------	------------------------